March 29, 2021 Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
February 8, 2021 In a recent podcast discussion with TrialSite News, Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, shares how the company’s experience in complex clinical research in resource-limited settings helps to ensure health equity and get life-saving vaccines to those who need them most.
November 20, 2020 The U.S. FDA granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized adults and children at least two years of age requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
October 20, 2020 Rob King of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the Oracle Health Sciences and FHI Clinical collaboration to improve clinical trial efficiency and help get therapies to market faster.
October 16, 2020 Development and ongoing activities of the China Tuberculosis Clinical Trials Consortium (CTCTC) were described in an article published in the Infectious Diseases of Poverty journal earlier this year. Read more, including FHI Clinical's role in providing the network with technical support and guidance for clinical trial capacity building.
October 12, 2020 Oracle Health Sciences and FHI Clinical Inc. have joined efforts to improve clinical trial efficiency and help get therapies to market faster. FHI Clinical has adopted Oracle Health Sciences Clinical One for randomization, supply management, and data collection; Oracle Argus Safety for safety case management; Oracle CTMS Cloud Service to manage the entire research portfolio; and Oracle ClearTrial Cloud Service to help budget, plan and bid on projects.
October 8, 2020 Final results of the Adaptive COVID-19 Treatment Trial (ACTT)-1 investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement have been published in the New England Journal of Medicine (NEJM). Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for their contributions to the study.
September 16, 2020 The operational goal is to provide experienced oversight while advancing the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network toward long-term, local self-sustainability - to conduct high-quality research with a focus on emergent and high-impact public health research priorities in Liberia.
August 4, 2020 FHI Clinical is pleased to announce our partnership with Tiziana Life Sciences to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
July 23, 2020 Claudia Christian of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer Research for the ongoing ACTT adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults.